{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:23:41Z","timestamp":1776803021581,"version":"3.51.2"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.mehy.2020.110452","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T01:18:16Z","timestamp":1607476696000},"page":"110452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?"],"prefix":"10.1016","volume":"146","author":[{"given":"Fotios","family":"Barkas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Liberopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.110452_b0005","unstructured":"WHO. Coronavirus disease (COVID-19) pandemic. Assessed from https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 on 11 May 2020; 2020."},{"key":"10.1016\/j.mehy.2020.110452_b0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"2020","key":"10.1016\/j.mehy.2020.110452_b0015","first-page":"1239","article-title":"Characteristics of and important lessons from the coronavirus disease, (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110452_b0020","article-title":"Cardiovascular disease, drug therapy, and mortality in covid-19","author":"Mehra","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01157-2020","article-title":"The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients","volume":"56","author":"Vicenzi","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.mehy.2020.110452_b0030","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110452_b0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110452_b0040","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","volume":"5","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.mehy.2020.110452_b0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0050","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2020","key":"10.1016\/j.mehy.2020.110452_b0055","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease, (COVID-19): a review","volume":"323","author":"Sanders","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110452_b0060","article-title":"Dexamethasone in hospitalized patients with covid-19 \u2013 preliminary report","author":"Group","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0065","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Lamontagne","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.mehy.2020.110452_b0070","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2013 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0075","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110452_b0080","article-title":"Remdesivir for severe covid-19: a clinical practice guideline","volume":"370","author":"Rochwerg","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.mehy.2020.110452_b0085","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00660-18","article-title":"et al.Statins suppress ebola virus infectivity by interfering with glycoprotein processing","volume":"9","author":"Shrivastava-Ranjan","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.mehy.2020.110452_b0090","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5114\/aoms.2020.94655","article-title":"Statins and the COVID-19 main protease: in silico evidence on direct interaction","volume":"16","author":"Reiner","year":"2020","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.mehy.2020.110452_b0095","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bcp.2014.11.013","article-title":"Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications","volume":"93","author":"Tikoo","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mehy.2020.110452_b0100","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0105","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110452_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2020.08.004","article-title":"Meta-analysis of effect of statins in patients with COVID-19","author":"Kow","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.mehy.2020.110452_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression","volume":"50","author":"Labonte","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.mehy.2020.110452_b0120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2019.03.002","article-title":"PCSK9 in HIV infection: new opportunity or red herring?","volume":"284","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mehy.2020.110452_b0125","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1128\/JVI.02727-13","article-title":"Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation","volume":"88","author":"Syed","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.mehy.2020.110452_b0130","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002683","article-title":"HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent \u201cPCSK9-lipid paradox\u201d","volume":"5","author":"Kohli","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.mehy.2020.110452_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154498","article-title":"Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes","volume":"11","author":"Ramanathan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2020.110452_b0140","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0145","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0150","doi-asserted-by":"crossref","first-page":"12169","DOI":"10.1128\/JVI.00835-07","article-title":"Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells","volume":"81","author":"Barman","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.mehy.2020.110452_b0155","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1007\/s00705-017-3545-4","article-title":"Cellular cholesterol is required for porcine nidovirus infection","volume":"162","author":"Jeon","year":"2017","journal-title":"Arch Virol"},{"key":"10.1016\/j.mehy.2020.110452_b0160","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s00705-018-3967-7","article-title":"Cholesterol is important for the entry process of porcine deltacoronavirus","volume":"163","author":"Jeon","year":"2018","journal-title":"Arch Virol"},{"key":"10.1016\/j.mehy.2020.110452_b0165","article-title":"The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain","volume":"12","author":"Guo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2020.110452_b0170","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s15010-017-1022-3","article-title":"Lipid testing in infectious diseases: possible role in diagnosis and prognosis","volume":"45","author":"Filippas-Ntekouan","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.mehy.2020.110452_b0175","article-title":"The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis","volume":"8","author":"Khan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2020.110452_b0180","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/CCM.0b013e31821b8290","article-title":"Understanding the potential role of statins in pneumonia and sepsis","volume":"39","author":"Yende","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.mehy.2020.110452_b0185","doi-asserted-by":"crossref","first-page":"E367","DOI":"10.1503\/cmaj.111017","article-title":"The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial","volume":"184","author":"Novack","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.mehy.2020.110452_b0190","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cmi.2018.11.003","article-title":"Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults \u2013 a systematic review and meta-analysis","volume":"25","author":"Pertzov","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mehy.2020.110452_b0195","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jama.2013.280031","article-title":"Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial","volume":"310","author":"Papazian","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110452_b0200","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.antiviral.2013.06.018","article-title":"Treating influenza with statins and other immunomodulatory agents","volume":"99","author":"Fedson","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.mehy.2020.110452_b0205","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/infdis\/jiu474","article-title":"A practical treatment for patients with Ebola virus disease","volume":"211","author":"Fedson","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mehy.2020.110452_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018120","article-title":"Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease","volume":"6","author":"Brett","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2020.110452_b0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/infdis\/jir695","article-title":"Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study","volume":"205","author":"Vandermeer","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mehy.2020.110452_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210808","article-title":"PCSK9 loss-of-function variants and risk of infection and sepsis in the reasons for geographic and racial differences in stroke (REGARDS) cohort","volume":"14","author":"Mitchell","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2020.110452_b0225","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110452_b0230","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110452_b0235","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement","volume":"253","author":"Ferri","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mehy.2020.110452_b0240","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as a positive modulator of platelet activation","volume":"71","author":"Camera","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.mehy.2020.110452_b0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.mehy.2020.110452_b0250","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cvr\/cvw194","article-title":"Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering","volume":"112","author":"Norata","year":"2016","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.mehy.2020.110452_b0255","article-title":"Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways","author":"Koushki","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.mehy.2020.110452_b0260","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2014.02.091","article-title":"Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4\/MYD88 pathway","volume":"446","author":"Yuan","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.mehy.2020.110452_b0265","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00638-15","article-title":"Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection","volume":"6","author":"Totura","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.mehy.2020.110452_b0270","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/JVI.02576-13","article-title":"Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival","volume":"88","author":"DeDiego","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.mehy.2020.110452_b0275","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13543784.2017.1272570","article-title":"PCSK9 inhibitors in sepsis: a new potential indication?","volume":"26","author":"Momtazi","year":"2017","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.mehy.2020.110452_b0280","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J Innate Immun"},{"key":"10.1016\/j.mehy.2020.110452_b0285","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","article-title":"Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial","volume":"6","author":"Calfee","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.mehy.2020.110452_b0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.mehy.2020.110452_b0295","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001451","article-title":"COVID-19-associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches","author":"Sorokin","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2020.110452_b0300","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/MOL.0000000000000642","article-title":"Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL","volume":"30","author":"Bonacina","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.mehy.2020.110452_b0305","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110452_b0310","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2020.110452_b0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1074248417724868","article-title":"Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables","volume":"23","author":"Filippatos","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.mehy.2020.110452_b0320","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/eurheartj\/ehaa325","article-title":"Deleterious effects of viral pneumonia on cardiovascular system","volume":"41","author":"Duan","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mehy.2020.110452_b0325","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.mehy.2020.110452_b0330","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharmthera.2009.01.002","article-title":"Statins and cardioprotection\u2013more than just lipid lowering?","volume":"122","author":"Ludman","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mehy.2020.110452_b0335","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cardiores.2007.02.029","article-title":"Do statins have an antiarrhythmic activity?","volume":"75","author":"Kostapanos","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.mehy.2020.110452_b0340","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10741-007-9041-2","article-title":"Should a statin be prescribed to every patient with heart failure?","volume":"13","author":"Tsouli","year":"2008","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.mehy.2020.110452_b0345","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/joim.13070","article-title":"Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk","volume":"287","author":"Vuorio","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.mehy.2020.110452_b0350","unstructured":"Cardiology ESo. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Assessed from https:\/\/www.escardio.org\/Education\/COVID-19-and-Cardiology\/ESC-COVID-19-Guidance#p09 on 10 June 2020."},{"key":"10.1016\/j.mehy.2020.110452_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104891","article-title":"Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic","volume":"158","author":"Banach","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.mehy.2020.110452_b0360","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0365","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibition on the risk of venous thromboembolism","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2020.110452_b0370","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2020.10.014","article-title":"Endothelial dysfunction in COVID-19: current findings and therapeutic implications","volume":"314","author":"Nagele","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mehy.2020.110452_b0375","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMc2009020","article-title":"ST-segment elevation in patients with covid-19 \u2013 a case series","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0380","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamacardio.2020.3551","article-title":"Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases","volume":"5","author":"Lindner","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.mehy.2020.110452_b0385","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1089\/ars.2013.5430","article-title":"Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering","volume":"20","author":"Margaritis","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.mehy.2020.110452_b0390","unstructured":"Meddeb MBR, Gerstenblith G, Leucker T. Are PCSK9 inhibitors the next front-line therapies to improve vascular dysfunction in people with pro-inflammatory states? Assessed from: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/10\/02\/12\/59\/are-pcsk9-inhibitors-the-next-front-line-therapies-to-improve-vascular-dysfunction on 02 Oct 2020."},{"key":"10.1016\/j.mehy.2020.110452_b0395","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016263","article-title":"Evolocumab, a PCSK9-monoclonal antibody rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia","volume":"9","author":"Leucker","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.mehy.2020.110452_b0400","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0405","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of covid-19 in New York City","volume":"382","author":"Goyal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110452_b0410","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.kint.2020.05.006","article-title":"Acute kidney injury in patients hospitalized with COVID-19","volume":"98","author":"Hirsch","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.mehy.2020.110452_b0415","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1111\/j.1559-4572.2008.00052.x","article-title":"Statin pleiotropy against renal injury","volume":"4","author":"Kostapanos","year":"2009","journal-title":"J Cardiometab Syndr"},{"key":"10.1016\/j.mehy.2020.110452_b0420","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/03007995.2017.1372157","article-title":"Uric acid and incident chronic kidney disease in dyslipidemic individuals","volume":"34","author":"Barkas","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mehy.2020.110452_b0425","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.mehy.2020.110452_b0430","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720333430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720333430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:21:00Z","timestamp":1759692060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720333430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":86,"alternative-id":["S0306987720333430"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110452","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110452"}}